Adaptix wins CE mark for Ortho350, opening UK and EU markets
Avingtrans (AIM:AVG)'s medical imaging subsidiary Adaptix received CE certification for its Ortho350 device, clearing the path for commercial sales across the UK and European markets. The mark represents the most significant regulatory hurdle for the product and positions Adaptix to begin converting pipeline interest into revenue-generating contracts in both territories.
Avingtrans shares edged up 1.35% to 648.61p on the news. The CE approval follows a period of investment in the Adaptix unit and signals that the group's strategy of building a commercialisable imaging technology is moving into its next phase.
Physiomics appoints AstraZeneca programme leader as transformation consultant
Physiomics (AIM:PYC) appointed Stewart Williams as a consultant to support its senior leadership transition. Williams brings more than 30 years of experience and is currently Head of Planning on AstraZeneca's AXIAL programme, a capital project valued at approximately $2 billion. His engagement is framed as providing continuity and strategic direction as the company manages changes at the top of its organisation.
The shares fell 8.66% to 0.58p on the day. The appointment signals that Physiomics is drawing on external expertise with a track record in large-scale life sciences operations as it works through its transition.
IXICO upgrades neuroimaging platform to boost precision and throughput
IXICO (AIM:IXI) released an upgraded version of its neuroimaging processing technology, delivering improvements in image-reading precision and a meaningful increase in throughput capacity. The technical enhancements also lay the groundwork for the company to offer the platform to partners and licensees, a commercial expansion that follows the recently announced collaboration with Medidata.
The shares rose 4.0% to 6.89p. The upgrade positions IXICO to scale its offering beyond its existing client base, with the Medidata partnership providing an early proof point for the licensing model the company is now actively building toward.
Novo Nordisk STEP UP data shows 27.7% weight loss in early Wegovy responders
A sub-analysis of the STEP UP trial presented at the European Congress on Obesity showed that patients who achieved weight loss of ≥15% by week 24 on semaglutide 7.2 mg went on to lose an average of 27.7% of body weight by week 72. A separate analysis from the same dataset found that the majority of weight lost comprised fat rather than lean muscle mass, a finding with clinical significance for the drug's long-term metabolic profile.
The data reinforces the differentiated efficacy case for Novo Nordisk's higher-dose Wegovy formulation and adds to the body of evidence supporting the STEP UP programme's commercial and regulatory trajectory. Early responders at the 24-week mark appear to sustain and compound their losses substantially over the following year.
